Samsung Bioepis strikes deal for Stelara biosimilar, but launch likely won’t come in time for an IRA exemption

Samsung Bioepis reached a deal this week that would allow its Stelara biosimilar hopeful to launch in February 2025, adding to mounting competition against Johnson & Johnson’s anti-inflammatory blockbuster.

However, it’s unlikely the candidate — or others under launch settlements with J&J — will amount to “meaningful competition” that would…
Click here to view original post